UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

Nature biotechnology, 2015-07, Vol.33 (7), p.733-735

2015

Volltextzugriff (PDF)

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates

Molecular cancer therapeutics, 2017-01, Vol.16 (1), p.116-123

2017

Volltextzugriff (PDF)

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Nature biotechnology, 2003-07, Vol.21 (7), p.778-784

2003

Volltextzugriff (PDF)

Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity

Bioconjugate chemistry, 2006-01, Vol.17 (1), p.114-124

2006

Volltextzugriff (PDF)

Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates

The Journal of biological chemistry, 2006-04, Vol.281 (15), p.10540-10547

2006

Volltextzugriff (PDF)

In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate

Clinical cancer research, 2005-01, Vol.11 (2), p.843-852

2005

Volltextzugriff (PDF)

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

Nature biotechnology, 2014-10, Vol.32 (10), p.1059-1062

2014

Volltextzugriff (PDF)

Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates

Clinical cancer research, 2004-12, Vol.10 (23), p.7842-7851

2004

Volltextzugriff (PDF)

Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models

Molecular cancer therapeutics, 2021-02, Vol.20 (2), p.320-328

2021

Volltextzugriff (PDF)

Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation

Bioconjugate chemistry, 2024-06, Vol.35 (6), p.855-866

2024

Volltextzugriff (PDF)

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Blood, 2003-08, Vol.102 (4), p.1458-1465

2003

Volltextzugriff (PDF)

Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate

Bioconjugate chemistry, 2008-10, Vol.19 (10), p.1960-1963

2008

Volltextzugriff (PDF)

Towards a general triple helix mediated DNA recognition scheme

Chemical Society reviews, 1997, Vol.26 (1), p.63-?

1997

Volltextzugriff (PDF)

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (4), p.2328-2337

2006

Volltextzugriff (PDF)

Dipeptide-based highly potent doxorubicin antibody conjugates

Bioorganic & medicinal chemistry letters, 2006-01, Vol.16 (2), p.358-362

2006

Volltextzugriff (PDF)

Abstract 4476: Novel auristatins with improved tolerability and unique bystander activity profile

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.4476-4476

2024

Volltextzugriff (PDF)

Abstract 648: Optimization of a PEGylated glucuronide-auristatin linker for antibody-drug conjugates

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.648-648

2015

Volltextzugriff (PDF)

Abstract 1786: Development and pharmacological properties of PEGylated glucuronide-auristatin linkers

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1786-1786

2014

Volltextzugriff (PDF)

Abstract 4470: Elucidating the role of drug-linker hydrophobicity in the disposition of antibody-drug conjugates

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4470-4470

2014

Volltextzugriff (PDF)

Abstract 4333: Self-stabilizing ADCs: antibody-drug conjugates prepared with maleimido drug-linkers that catalyze their own thiosuccinimide ring hydrolysis

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4333-4333

2013

Volltextzugriff (PDF)

Abstract 2831: Novel antibody-drug conjugates for selective tumor activation

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2831-2831

2011

Volltextzugriff (PDF)

Erratum: Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Nature biotechnology, 2003-08, Vol.21 (8), p.941-941

2003

Volltextzugriff (PDF)

Synthesis of C-4 substituted pyrimidines exhibiting various H-bonding patterns

Tetrahedron letters, 1999-08, Vol.40 (34), p.6229-6232

1999

Volltextzugriff (PDF)

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Nature biotechnology, 2003-08, Vol.21 (8), p.941-941

2003

Volltextzugriff (PDF)

EFFICIENT SYNTHESIS OF OLIGONUCLEOTIDE-PEPTIDE CONJUGATES ON LARGE SCALE

Nucleosides, nucleotides & nucleic acids, 2001-04, Vol.20 (4-7), p.1007-1010

2001

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(9)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity

Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates

In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates

Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models

Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate

Towards a general triple helix mediated DNA recognition scheme

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates

Dipeptide-based highly potent doxorubicin antibody conjugates

Abstract 4476: Novel auristatins with improved tolerability and unique bystander activity profile

Abstract 648: Optimization of a PEGylated glucuronide-auristatin linker for antibody-drug conjugates

Abstract 1786: Development and pharmacological properties of PEGylated glucuronide-auristatin linkers

Abstract 4470: Elucidating the role of drug-linker hydrophobicity in the disposition of antibody-drug conjugates

Abstract 4333: Self-stabilizing ADCs: antibody-drug conjugates prepared with maleimido drug-linkers that catalyze their own thiosuccinimide ring hydrolysis

Abstract 2831: Novel antibody-drug conjugates for selective tumor activation

Erratum: Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Synthesis of C-4 substituted pyrimidines exhibiting various H-bonding patterns

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

EFFICIENT SYNTHESIS OF OLIGONUCLEOTIDE-PEPTIDE CONJUGATES ON LARGE SCALE

Suchergebnisse filtern